Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

229 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Interest of integrins targeting in glioblastoma according to tumor heterogeneity and cancer stem cell paradigm: an update.
Malric L, Monferran S, Gilhodes J, Boyrie S, Dahan P, Skuli N, Sesen J, Filleron T, Kowalski-Chauvel A, Cohen-Jonathan Moyal E, Toulas C, Lemarié A. Malric L, et al. Among authors: filleron t. Oncotarget. 2017 Aug 21;8(49):86947-86968. doi: 10.18632/oncotarget.20372. eCollection 2017 Oct 17. Oncotarget. 2017. PMID: 29156849 Free PMC article. Review.
αvβ3 Integrin and Fibroblast growth factor receptor 1 (FGFR1): Prognostic factors in a phase I-II clinical trial associating continuous administration of Tipifarnib with radiotherapy for patients with newly diagnosed glioblastoma.
Ducassou A, Uro-Coste E, Verrelle P, Filleron T, Benouaich-Amiel A, Lubrano V, Sol JC, Delisle MB, Favre G, Ken S, Laprie A, De Porre P, Toulas C, Poublanc M, Cohen-Jonathan Moyal E. Ducassou A, et al. Among authors: filleron t. Eur J Cancer. 2013 Jun;49(9):2161-9. doi: 10.1016/j.ejca.2013.02.033. Epub 2013 Apr 6. Eur J Cancer. 2013. PMID: 23566417 Clinical Trial.
Evaluation of the lactate-to-N-acetyl-aspartate ratio defined with magnetic resonance spectroscopic imaging before radiation therapy as a new predictive marker of the site of relapse in patients with glioblastoma multiforme.
Deviers A, Ken S, Filleron T, Rowland B, Laruelo A, Catalaa I, Lubrano V, Celsis P, Berry I, Mogicato G, Cohen-Jonathan Moyal E, Laprie A. Deviers A, et al. Among authors: filleron t. Int J Radiat Oncol Biol Phys. 2014 Oct 1;90(2):385-93. doi: 10.1016/j.ijrobp.2014.06.009. Epub 2014 Aug 4. Int J Radiat Oncol Biol Phys. 2014. PMID: 25104068 Clinical Trial.
Key contribution of eIF4H-mediated translational control in tumor promotion.
Vaysse C, Philippe C, Martineau Y, Quelen C, Hieblot C, Renaud C, Nicaise Y, Desquesnes A, Pannese M, Filleron T, Escourrou G, Lawson M, Rintoul RC, Delisle MB, Pyronnet S, Brousset P, Prats H, Touriol C. Vaysse C, et al. Among authors: filleron t. Oncotarget. 2015 Nov 24;6(37):39924-40. doi: 10.18632/oncotarget.5442. Oncotarget. 2015. PMID: 26498689 Free PMC article.
CD163-positive tumor-associated macrophages and CD8-positive cytotoxic lymphocytes are powerful diagnostic markers for the therapeutic stratification of osteosarcoma patients: An immunohistochemical analysis of the biopsies fromthe French OS2006 phase 3 trial.
Gomez-Brouchet A, Illac C, Gilhodes J, Bouvier C, Aubert S, Guinebretiere JM, Marie B, Larousserie F, Entz-Werlé N, de Pinieux G, Filleron T, Minard V, Minville V, Mascard E, Gouin F, Jimenez M, Ledeley MC, Piperno-Neumann S, Brugieres L, Rédini F. Gomez-Brouchet A, et al. Among authors: filleron t. Oncoimmunology. 2017 Aug 24;6(9):e1331193. doi: 10.1080/2162402X.2017.1331193. eCollection 2017. Oncoimmunology. 2017. PMID: 28932633 Free PMC article.
229 results